
AMPED
Healthcare · Biotechnology · $7.7M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 9, 2022 | After the close | -0.02 | -0.01 | +50.0% |
| May 16, 2022 | After the close | -0.02 | -0.02 | 0.0% |
| Mar 29, 2022 | After the close | -0.02 | -0.04 | -100.0% |
| Nov 10, 2021 | After the close | -0.02 | -0.02 | 0.0% |
| Aug 4, 2021 | After the close | -0.02 | -0.02 | 0.0% |
| May 5, 2021 | After the close | -0.02 | -0.02 | 0.0% |
| Mar 3, 2021 | After the close | -0.02 | -0.01 | +50.0% |
| Nov 3, 2020 | Before the open | — | -0.28 | — |
| Jul 31, 2020 | Before the open | -0.04 | -0.02 | +50.0% |
| May 6, 2020 | After the close | -0.04 | -0.04 | 0.0% |
| Feb 21, 2020 | Before the open | -0.04 | -0.01 | +75.0% |
| Nov 7, 2019 | After the close | -0.04 | -0.05 | -25.0% |
| Aug 9, 2019 | After the close | — | -0.45 |
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to…
| — |
| May 10, 2019 | After the close | — | -0.78 | — |
| Mar 18, 2019 | After the close | — | 0.21 | — |
| Nov 14, 2018 | Before the open | — | 0.90 | — |
| Aug 13, 2018 | After the close | — | 0.80 | — |
| May 10, 2018 | Before the open | — | 3.99 | — |
| Mar 6, 2018 | After the close | — | -8.64 | — |